A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and…
A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and hospitalization risk by 47.0% compared to Pfizer/BioNTech's BNT162b2 in older veterans during the 2025-2026 season. The study included 294,499 participants, with mRNA-1283 showing better outcomes across various metrics. Moderna supported the study, which was conducted by independent investigators.
How this was made

The 30-second read
Why it matters
The findings provide new real-world comparative effectiveness data that could influence investor sentiment toward both vaccine makers.
Market read
New comparative effectiveness data could shift market perception of COVID-19 vaccine leaders, impacting stock valuations.
What to watch
Study limited to older US veterans; results may not generalize to broader populations.
Background
A JAMA Network Open study compared Moderna's mRNA-1283 vaccine to Pfizer's BNT162b2 in older US veterans, finding a 35.9% lower risk of medically attended COVID-19 and a 47% lower risk of hospitalization for Moderna.
Ticker impact
Moderna's mRNA-1283 vaccine showed 35.9% lower risk of medically attended COVID-19 versus Pfizer in the study.
likely upside as data supports superior efficacy
New comparative effectiveness data could improve market perception and drive buying pressure.
Pfizer's BNT162b2 vaccine showed higher risk of COVID-19 outcomes compared to Moderna in the same study.
potential downside as study shows lower effectiveness
Study results could raise concerns about Pfizer's vaccine competitiveness, pressuring the stock.
Market effects
COVID-19 vaccine market may shift favoring Moderna's product.
US biotech sector could see revaluation based on efficacy data.
Global vaccine competition dynamics may be affected by the study.
Counterpoint
Pfizer's broader portfolio and other vaccine candidates may offset concerns from this single study.
Key entities
- CompanyModerna Inc.
Developer of the mRNA-1283 vaccine.
- CompanyPfizer Inc.
Manufacturer of the BNT162b2 (Comirnaty) vaccine.
- PublicationJAMA Network Open
Journal publishing the comparative effectiveness study.
- OrganizationVeterans Health Administration
Source of the veteran cohort used in the study.





